Androgen deprivation therapy suppresses the progression of hormone‐sensitive prostate cancer through the inhibition of AR signaling, although prostate cancer often acquires resistance to androgen deprivation therapy [2]. The gene discussed is AR; the disease is Familial prostate cancer.